Cargando…

Cost-effectiveness and cost-utility of traditional and telemedicine combined population-based age-related macular degeneration and diabetic retinopathy screening in rural and urban China

BACKGROUND: To assess the cost-effectiveness and cost-utility of a population-level traditional and telemedicine combined age-related macular degeneration (AMD) and diabetic retinopathy (DR) screening program in rural and urban China. METHODS: Decision-analytic Markov models were conducted to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ruyue, Yang, Ziwei, Zhang, Yue, Bai, Weiling, Du, Yifan, Sun, Runzhou, Tang, Jianjun, Wang, Ningli, Liu, Hanruo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958534/ https://www.ncbi.nlm.nih.gov/pubmed/35355615 http://dx.doi.org/10.1016/j.lanwpc.2022.100435

Ejemplares similares

Cost–utility analysis of commonly used anti-glaucoma interventions for mild-to-moderate primary open-angle glaucoma patients in rural and urban China
por: Li, Ruyue, et al.
Publicado: (2023)

Artificial Intelligence in Community-Based Diabetic Retinopathy Telemedicine Screening in Urban China: Cost-effectiveness and Cost-Utility Analyses With Real-world Data
por: Lin, Senlin, et al.
Publicado: (2023)

Resource Utilization and Costs of Age-Related Macular Degeneration
por: Halpern, Michael T., et al.
Publicado: (2006)

Cost-effectiveness and diagnostic accuracy of telemedicine in macular disease and diabetic retinopathy: A systematic review and meta-analysis
por: Ullah, Waqas, et al.
Publicado: (2020)

Diabetic retinopathy and age-related macular degeneration: a survey of pharmacoutilization and cost in Calabria, Italy
por: Scuteri, Damiana, et al.
Publicado: (2019)

Identification of the Optimal Model for the Prediction of Diabetic Retinopathy in Chinese Rural Population: Handan Eye Study
por: Jin, Shanshan, et al.
Publicado: (2022)

Cost-Utility Analyses of Cataract Surgery in Advanced Age-Related Macular Degeneration
por: Ma, Yingyan, et al.
Publicado: (2016)

Implementing a digital comprehensive myopia prevention and control strategy for children and adolescents in China: a cost-effectiveness analysis
por: Li, Ruyue, et al.
Publicado: (2023)

Telemedicine in diabetic retinopathy: Access to rural India
por: Das, Taraprasad, et al.
Publicado: (2016)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Age-Related Macular Degeneration and Diabetic Retinopathy
por: Ebneter, Andreas, et al.
Publicado: (2022)

Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review
por: Avidor, Daniel, et al.
Publicado: (2020)

The Cost-Effectiveness of a Telemedicine Screening Program for Diabetic Retinopathy in New York City
por: Muqri, Hasan, et al.
Publicado: (2022)

Cost-effectiveness of smoking cessation to prevent age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
por: Brown, Gary C., et al.
Publicado: (2015)

Healthcare Resource Utilization and Costs in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
por: Kim, Ashley, et al.
Publicado: (2021)

Diabetic macular edema, retinopathy and age-related macular degeneration as inflammatory conditions
por: Das, Undurti N.
Publicado: (2016)

Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons
por: Meer, Elana A, et al.
Publicado: (2022)

Telemedicine for the Diagnosis and Management of Age-Related Macular Degeneration: A Review
por: Armstrong, Grayson W., et al.
Publicado: (2022)

Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost–Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration
por: Brown, Gary C., et al.
Publicado: (2023)

The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea
por: Ho, Ra, et al.
Publicado: (2018)

Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
por: Romero-Aroca, Pedro, et al.
Publicado: (2016)

Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi
por: Vetrini, Damir, et al.
Publicado: (2018)

Early Patterns of Macular Degeneration in ABCA4-Associated Retinopathy
por: Khan, Kamron N., et al.
Publicado: (2018)

Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China
por: Huang, Xiao-Mei, et al.
Publicado: (2022)

Time Gain Needed for In-Ambulance Telemedicine: Cost-Utility Model
por: Valenzuela Espinoza, Alexis, et al.
Publicado: (2017)

Intraocular vision-improving devices in age-related macular degeneration
por: Grzybowski, Andrzej, et al.
Publicado: (2020)

Correction: The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea
por: Ra, Ho, et al.
Publicado: (2018)

Correction: The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea
por: Ra, Ho, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Acceptability, Feasibility, and Cost of Telemedicine for Nonacute Headaches: A Randomized Study Comparing Video and Traditional Consultations
por: Müller, Kai Ivar, et al.
Publicado: (2016)

Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review
por: Poku, Edith, et al.
Publicado: (2013)

Circulating biomarkers in glaucoma, age-related macular degeneration, and diabetic retinopathy
por: Nath, Madhu, et al.
Publicado: (2017)

Health care resource utilization and costs associated with atrial fibrillation and rural-urban disparities
por: Jiang, Shangqing, et al.
Publicado: (2022)

Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration
por: Chen, Rui, et al.
Publicado: (2020)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Cost-Utility Analysis of Screening Strategies for Diabetic Retinopathy in Korea
por: Kim, Sang-Won, et al.
Publicado: (2015)

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review
por: Muste, Justin C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8sjf0ave39e9djsf0grfqf1jcs